SCHEMBL1328337

SCHEMBL1328337

CN(c1ccccc1Br)c1ccccc1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
TAAR1 Q96RJ0 2/20 0.41
HTR7 P34969 2/20 0.38
ESR1 P03372 2/20 0.37
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
ALPL P05186 1/20 0.35
ALPI P09923 1/20 0.35
ALPG P10696 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.35
PYCR1 P32322 1/20 0.35
MAPK1 P28482 1/20 0.35
GAA P10253 2/20 0.34
MAPT P10636 2/20 0.34
TSHR P16473 2/20 0.34
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTR2A P28223 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14691249 0.85 PIM1 (0.39) ALDH1A1TAAR1MEN1NPC1ALPL
SCHEMBL545805 0.83 ALDH1A1 (0.44) ALDH1A1TAAR1HTR7ESR1MEN1
SCHEMBL29713864 0.83 ALDH1A1 (0.44) ALDH1A1TAAR1HTR7ESR1MEN1
SCHEMBL29828297 0.82 ESR1 (0.42) ALDH1A1TAAR1ESR1MEN1KMT2A
SCHEMBL28628553 0.82 TSHR (0.41) ALDH1A1TAAR1NPC1RAB9AKMT2A
SCHEMBL28984818 0.82 ESR1 (0.42) ALDH1A1TAAR1ESR1MEN1KMT2A
SCHEMBL27821582 0.81 MEN1 (0.42) ALDH1A1TAAR1HTR7ESR1MEN1
SCHEMBL10340767 0.81 MAPT (0.43) ALDH1A1TAAR1HTR7ESR1MEN1
Hydrochloric Acid SCHEMBL2872399 0.81 MAPT (0.43) ALDH1A1TAAR1HTR7ESR1MEN1
SCHEMBL4581592 0.79 ALDH1A1 (0.40) ALDH1A1TAAR1HTR7ESR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073948-B2 Azaborine compounds as host materials and dopants for PHOLEDs UNIVERSAL DISPLAY CORPORATION (US) 2015-07-07 US disclosed
US-9073948-B2 Azaborine compounds as host materials and dopants for PHOLEDs UNIVERSAL DISPLAY CORPORATION (US) 2015-07-07 US disclosed
US-20110279019-A1 AZABORININE COMPOUNDS AS HOST MATERIALS AND DOPANTS FOR PHOLEDS UNIVERSAL DISPLAY CORPORATION (US) 2011-11-17 US disclosed
US-20110278556-A1 Azaborinine Compounds As Host Materials And Dopants For PHOLEDs UNIVERSAL DISPLAY CORPORATION (US) 2011-11-17 US disclosed
WO-2011143563-A2 AZABORINE COMPOUNDS AS HOST MATERIALS AND DOPANTS FOR PHOLEDS UNIVERSAL DISPLAY CORPORATION (US) 2011-11-17 WO disclosed
WO-2011143563-A2 AZABORINE COMPOUNDS AS HOST MATERIALS AND DOPANTS FOR PHOLEDS UNIVERSAL DISPLAY CORPORATION (US) 2011-11-17 WO disclosed
US-20110278556-A1 Azaborinine Compounds As Host Materials And Dopants For PHOLEDs UNIVERSAL DISPLAY CORPORATION (US) 2011-11-17 US disclosed
US-20110279019-A1 AZABORININE COMPOUNDS AS HOST MATERIALS AND DOPANTS FOR PHOLEDS UNIVERSAL DISPLAY CORPORATION (US) 2011-11-17 US disclosed
US-20110279019-A1 AZABORININE COMPOUNDS AS HOST MATERIALS AND DOPANTS FOR PHOLEDS UNIVERSAL DISPLAY CORPORATION (US) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110279019-A1 AZABORININE COMPOUNDS AS HOST MATERIALS AND DOPANTS FOR PHOLEDS PAXBP1, PGLS, PPM1B ALDH1A1 3080/4885TAAR1 388/4885HTR7 795/4885
US-20110278556-A1 Azaborinine Compounds As Host Materials And Dopants For PHOLEDs PAXBP1, PGLS, PPM1B ALDH1A1 3080/4885TAAR1 388/4885HTR7 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.